Wendy Lam, BSc. (Pharm), MD, FRCPC
Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.
She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.
She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.
Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.
She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association.
She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association
David Liu, MD, FRCPC, FSIR
Associate Professor, Department of Radiology, Faculty of Medicine, University of British Columbia
Associate Professor, School of Biomedical Engineering, Faculty of Applied Sciences, University of British Columbia
Voluntary Professor, Department of Interventional Radiology, Miller School of Medicine, University of Miami
Dr. David M Liu MD is a board certified in both Canada and the US, practicing at the Vancouver General Hospital, University of British Columbia Hospital and the BC Cancer Agency with a cross appointment in the Department of Surgery. Dr. Liu received his medical degree from University of Toronto, completed his radiology residency at University of British Columbia, Interventional Radiology fellowship at Northwestern Memorial Hospital, and has practiced in both the US and Canada.
In addition to benchside and clinical research in the fields of novel embolic platforms, ablative technologies and cancer related thromboembolic disease, Dr. Liu maintains an interventional oncology practice incorporating all aspects of embolization, ablation, venous access, and palliative therapy in all organ systems. He is the co-founder and co-chair of the international liver cancer symposium, SHOW, and has been credited with 7 book chapters, over 70 publications, and over 100 invited lectures around the world. Dr. Liu an active member of the interventional radiology community as recognized through his induction as a Fellow of the Society of Interventional Radiology, and has been awarded the CIRA award from the Canadian Association of Interventional Radiology (CAIR) in recognition of his extraordinary contribution to the practice of IR in Canada and worldwide.
Dr. Liu holds numerous academic appointments including:
Associate Professor, Faculty of Medicine, Department of Radiology, University of British Columbia, Vancouver, Canada
Associate Professor, Faculty of Applied Sciences, School of Biomedical Engineering, University of British Columbia, Vancouver, Canada
Voluntary Professor, Miller School of Medicine, Department of Interventional Radiology, Miami, USA
Andrew Kennedy, MD, FACRO
Physician in Chief, Radiation Oncology, Sarah Cannon
Director, Radiation Oncology Research, Sarah Cannon Research Institute
Sarah Cannon Cancer Center
Dr. Kennedy joined Sarah Cannon in 2012 as the Physician in Chief, Radiation Oncology and Director, Radiation Oncology Research at Sarah Cannon Research Institute where he is responsible for strategic development of radiation oncology services for HCA Healthcare and development of radiation oncology research program within Sarah Cannon to complement the world-class medical oncology program. Dr. Kennedy is a graduate of the Loma Linda School of Medicine in California, and completed his residency at The University of North Carolina at Chapel Hill.
He is an internationally renowned radiation oncologist specializing in gastrointestinal cancers, as well as cancers of the breast and lung. Nationally, he served as a member of the Board of Chancellors for the American College of Radiation Oncology and is a Fellow of the College. He has been selected yearly since 2009 as one of America’s Best Doctors (top 5 percent of U.S.), and was inducted into Alpha Omega Alpha (AOA) Honor Society as a faculty member in 1999.
Peter TW Kim MD, MSc, FRCSC, FACS
Head, Hepatopancreatobiliary Surgery
Vancouver General Hospital
Clinical Associate Professor
University of British Columbia
Dr. Peter Kim is a liver transplant and a hepatopancreatobiliary (HPB) surgeon at the Vancouver General Hospital and an associate clinical professor of the Department of Surgery, University of British Columbia. He is the current head of the liver transplant and the HPB surgery program at the Vancouver General Hospital.
Dr. Kim received his medical degree from the University of Western Ontario in London, Ontario, Canada. He completed his general surgery residency and Masters of Sciences degree at the University of British Columbia. His research work focused on differentiating embryonic stem cells into insulin producing cells to treat diabetes. He subsequently completed his abdominal transplant surgery fellowship at Baylor University Medical Center, Dallas, Texas, followed by HPB surgery fellowship at the University of Toronto.
After his training, Dr. Kim worked at the Baylor University Medical Center as the assistant director of living donor liver transplantation for 5 years before returning to the Vancouver General Hospital to join the liver transplantation team. His clinical practice includes liver transplantation and hepatopancreatobiliary surgery.
Dr. Kim is an author of over 60 publications and 8 book chapters. His research interests include studying the importance of blood flow to the liver in liver transplantation, bile duct complications in liver transplantation and complex surgical resections in pancreas cancer surgery.
Howard Lim, MD, PhD, FRCPC
Clinical Associate Professor
Faculty of Medicine, UBC
BC Cancer- Vancouver Centre
Howard Lim is a Medical Oncologist at B.C Cancer – Vancouver Centre and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. He specializes in gastrointestinal malignancies and is actively involved in clinical trials, ethics and genomic based research.
Daniel Renouf, MD, MPH, FRCPC
Associate Professor, University of British Columbia
Executive Medical Director
BC Cancer, Vancouver Centre
Daniel Renouf is a medical oncologist and the Executive Medical Director at BC Cancer, Vancouver Centre. He is an Associate Professor at the University of British Columbia, Department of Medicine.
He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and BC Cancer. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University.
Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer. He is the leader of the BC Cancer Phase I program, the BC Cancer GI Tumour Group chair, the Co-Director of Pancreas Centre BC and is the Co-chair of the Canadian Cancer Trials Group Pancreatic Cancer disease group.
Vladimir Marquez, MDCM, M.Sc, FRCPC
Vancouver General Hospital
Dr. Vladimir Marquez is a member of the division of Gastroenterology at the Vancouver General Hospital. He complete his undergraduate and medical training as well as his Masters in Epidemiology at McGill University and residency training at Laval University. His expertise include liver transplantation, complications of portal hypertension and vascular liver disorders. He is also an active member of the liver tumor board at Vancouver General Hospital.
Benjamin A. Weinberg, MD, FACP
Associate Professor of Medicine, Division of Hematology and Oncology
Attending Physician, MedStar Georgetown University Hospital
Gastrointestinal Medical Oncologist
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Dr. Weinberg is an Associate Professor of Medicine and Attending Physician specializing in gastrointestinal medical oncology and sarcoma. Dr. Weinberg is focused on developing new therapies for colorectal and pancreatic cancers by translating research from animal models into early phase clinical trials in humans. He also studies young patients with colorectal cancer in order to understand the dramatic rise in incidence of left-sided colon and rectal cancers in this population.
Dr. Weinberg obtained his undergraduate degree in biomedical science at the University of Pennsylvania in 2007 and his MD at the Keck School of Medicine of the University of Southern California in 2011. He completed his post-graduate medical training at MedStar Georgetown University Hospital with a residency in internal medicine in 2014 and a fellowship in hematology and oncology in 2017 where he served as the Chief Fellow from 2016 to 2017.
Robert Lewandowski, M.D., FSIR
Professor of Radiology, Medicine, and Surgery
Feinberg School of Medicine, Northwestern University
Director, Interventional Oncology
Northwestern University Robert H. Lurie Comprehensive Cancer Center
Robert J. Lewandowski, M.D., FSIR, is a Professor of Radiology, Medicine, and Surgery in the Feinberg School of Medicine at Northwestern University. He serves as the Director of Interventional Oncology at the Northwestern University Robert H. Lurie Comprehensive Cancer Center. Dr. Lewandowski joined the staff at Northwestern in 2006 upon completion of his fellowship training in Vascular and Interventional Radiology. Dr. Lewandowski is a practicing interventional radiologist who specializes in liver-directed therapy. Based on his clinical oncology program, he has authored or co-authored > 150 articles for peer-reviewed journals on the application of liver-directed therapies for patients with gastrointestinal malignancies.
Dr. Lewandowski also performs pre-clinical oncology research in the Northwestern University Interventional Oncology Laboratory and Center for Translational Imaging. In this capacity, he is developing and evaluating novel oncology therapeutics, delivery mechanisms, and imaging modalities. Dr. Lewandowski’s work has been supported by the National Institute of Health, American Cancer Society, the Society of Interventional Radiology Foundation, and industry collaboration via the investigator-initiated trial mechanism.
Govindarajan (Raj) Narayanan, MD
Interventional Radiologist, Miami Cardiac and Vascular Institute
Chief of Interventional Oncology, Miami Cancer Institute
Dr. Narayanan is an Interventional Radiologist at the Miami Cardiac and Vascular Institute and the Chief of Interventional Oncology at the Miami Cancer Institute. Dr. Narayanan is board-certified in diagnostic radiology and holds a Certificate of Added Qualification in interventional radiology.
Most recently, he served as medical director of Interventional Radiology at University of Miami Hospital and Clinics, and as the founding chairman of the Department of Interventional Radiology at the University Of Miami Miller School Of Medicine, where he also served as a Professor of interventional Radiology.
Dr. Narayanan’s primary clinical research interests include pancreatic, liver and colon cancer. He is widely published in such high-impact medical journals as Cancer, Journal if Vascular and Interventional Radiology and Cardiovascular and Interventional Radiology and serves as a reviewer and editor for several scientific publications. He has authored text book chapters and is an invited faculty member and speaker at national and international scientific meetings.
Jason Wong, MD
Clinical Associate Professor,
Cumming School of Medicine, University of Calgary
Partner, EFW Radiology
Tertiary Care Hospital, Foothills Medical Centre
Calgary, AB .
Dr. Jason Wong is an Interventional Radiologist working as a partner of EFW Radiology. He is based at the tertiary care hospital, Foothills Medical Centre, in Calgary and is a Clinical Associate Professor at the Cumming School of Medicine at the University of Calgary.
Dr. Wong is a Past President for the Canadian Association for Interventional Radiology (CAIR) and has been on the CIRA board since 2011. He continues to serve on many other local and provincial committees. He is also a past board member for the Canadian Association of Radiologists (CAR).
Dr. Wong is an elected as a Fellow of the Society of Interventional Radiology (SIR), and also a fellow of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) one of the highest honours bestowed to both organizations.
Additionally, Dr. Wong is involved in teaching medical students, residents, and fellows at the University of Calgary. Dr. Wong was the fellowship director for the Department of Radiology of the University of Calgary from 2008-2014, and has been an active member of its Residency Program Committee since 2007. Dr. Wong is a current examiner for Diagnostic Radiology at the Royal College of Physicians and Surgeons of Canada.
Dr. Wong completed an Interventional Radiology fellowship at Stanford University School of Medicine, in California, where he also did a mini cardiac imaging fellowship.
Dr. Wong’s practice is focused on interventional oncology treatments (and brought the Y90/TARE program to Calgary). He is also interested in venous disease, women’s health, and cardiovascular imaging.
Dr. Wong enjoys spending time with his wife Seline and their two sons, Logan and Luke. The family can be seen wake surfing, skiing, and golfing.
Mark J. Truty, M.D., M.Sc.
Associate Professor, Consultant Division of Hepatobiliary and Pancreas Surgery Department of Surgery
Mayo Clinic College of Medicine
Mark J. Truty, M.D., M.S., is a Consultant and the Practice Chair of the Division of Hepatobiliary and Pancreatic Surgery at Mayo Clinic in Rochester, Minnesota. He is the Chair of Revenue and Compliance for the Department of Surgery and is also the Director of the Hepatobiliary, Pancreatic, and GI Malignancy Patient-Derived Xenograft Program, a benefactor-supported venture. Dr. Truty joined the staff of Mayo Clinic in 2012 and holds the academic rank of Associate Professor of Surgery, Mayo Clinic College of Medicine and Science.
Dr. Truty earned his Bachelor of Science degree in biological sciences at the University of Chicago. He completed his Master of Science degrees in Physiology and Anatomic Pathology as well as his Doctor of Medicine degree at the Chicago Medical School. At Mayo Clinic, he completed his five-year general surgery residency along with a two-year Clinical-Investigator postdoctoral fellowship studying transcriptional control of pancreatic cancer. He subsequently completed a two-year clinical fellowship in Complex Surgical Oncology as well as a oneyear translational research fellowship in Patient-Based Biological Research at University of Texas MD Anderson Cancer Center.
Dr. Truty specializes in the multidisciplinary surgical treatment of advanced pancreatic, liver, and other aggressive abdominal/retroperitoneal cancers with special expertise in traditionally ‘inoperable’ tumors requiring vascular resection. His clinical research focus is on the optimization of initial staging of pancreatic cancer, developing and validating novel methods to predict responses to neoadjuvant therapy, studying and improving the outcomes of patients undergoing major resection for complex tumors, identifying ideal therapeutic treatment sequencing to derive maximal survival and quality-of-life benefits, as well as evaluation of novel molecular methods to prevent and treat complications associated with oncologic surgery. His translational research focuses on predictive and patient-relevant models of therapeutic treatment efficacy with biomarker discovery and validation for early diagnostics, therapeutics, and surveillance using his PDX program. He has served as institutional PI on several national clinical trials and has R01 NIH funding for multi-center clinical trial using novel metabolic imaging and molecular staging assays in pancreatic cancer.
Dr. Truty is frequently invited to give presentations on his clinical and research endeavors both domestically and internationally. He holds reviewer responsibilities for several prominent publications and has authored numerous peer-reviewed journal articles, book chapters, and abstracts. In recognition of his work, Dr. Truty has received many awards and honors, including Teacher of the Year awards conferred by the Mayo Clinic General Surgery Residency Program. He has also received the Donald C. Balfour Most Outstanding Research Award, conferred by Mayo Clinic School of Graduate Medical Education, as well as numerous Best Presentation awards by various surgical organizations.
Dr. Truty is a fellow of the American College of Surgeons. His memberships with professional organizations include the American Society of Clinical Oncology, Society of Surgical Oncology, Pancreas Club, and Americas Hepato-Pancreato-Biliary Association, where he serves on the Program Committee.
Jean-Nicolas Vauthey, MD, FACS
Chief, Hepato-Pancreato-Biliary Section
Dallas/Fort Worth Living Legend Chair, Cancer Research, Department of Surgical Oncology, Division of Surgery
The University of Texas MD Anderson Cancer Center
Dr. Vauthey is Chief of the Hepato-Pancreato-Biliary section and Dallas/Fort Worth Living Legend Chair for Cancer Research, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center. His clinical research has focused on methods to measure and to improve outcome after hepatic resection for hepatobiliary malignancies. He has co-authored more than 600 publications in peer-reviewed journals (h-index, 116) and more than 100 reviews and book chapters in major textbooks. Dr. Vauthey is editor of major textbooks devoted to the treatment of liver diseases. Dr. Vauthey is Chair of The American Joint Committee on Cancer Hepatobiliary and Pancreas Task Force for the 8th Edition of the Manual for Staging Cancer. Dr. Vauthey is the current President of the Society for Surgery of the Alimentary Tract and the past President of the Americas Hepato-Pancreato-Biliary Association. Dr. Vauthey is on the editorial board of the Journal of the American College of Surgeons, Surgery, Annals of Surgery, Annals of Surgical Oncology and the Journal of Gastrointestinal Surgery.
Kyle Cuneo, MD
Associate Professor, Radiation Oncology
University of Michigan
Dr. Cuneo performs basic science, translational, and clinical research at the University of Michigan. His research focuses on the development of novel therapeutic approaches and biomarker discovery in gastrointestinal cancers. He serves as the principal investigator on clinical trials in pancreatic cancer, hepatocellular carcinoma, and colorectal cancer.
Navesh K. Sharma, DO, PhD, FACRO
Associate Professor, Radiation Oncology
Professor & Associate Chair for Community Academics
Department of Radiation Oncology
Penn State College of Medicine/Cancer Institute
Director of Radiation Oncology
Penn State Health St. Joseph Cancer Center
Dr. Sharma is a Board Certified radiation oncologist and Director of Radiation Oncology at Penn State Health St. Joseph Cancer Center, also leading the liver directed therapy program there. Additionally, he is a Professor and Associate Chair for Community Academics in the Department of Radiation Oncology at Penn State University College of Medicine/Penn State Cancer Institute in Hershey, PA. Dr. Sharma served as the United States Principal Investigator for the FOXFIRE Global international trial assessing the role of first-line Y90 radioembolization in liver predominant metastatic colorectal cancer and has been widely published for his expertise with liver-directed and other gastrointestinal radiation therapy treatments. He serves on several national guideline and appropriate use committees for gastrointestinal cancers and is the GI disease site team leader for the American College of Radiation Oncology’s practice accreditation program. His academic interests revolve around improving multidisciplinary management of gastrointestinal malignancies and appropriate adoption of technological advancements in radiation treatment delivery.